
Greenwich Lifesciences (GLSI) Stock Forecast & Price Target
Greenwich Lifesciences (GLSI) Analyst Ratings
Bulls say
Greenwich LifeSciences is viewed positively because its Phase III FLAMINGO-01 program is generating encouraging efficacy and immune-response signals, including a 70–80% recurrence reduction in the fully enrolled 247-patient non-HLA-A*02 arm and a DTH increase from 5.2% to 20.4% in 191 patients. The recent FDA and EMA protocol changes that combine HLA types in the randomized arms, plus UK expansion, broaden eligibility to about 55% more patients and could lift enrollment by up to 122%, improving event accrual and shortening the path to interim readouts. Despite a 3Q26 net loss of $5.8M, or ($0.40) per share, these operational catalysts, along with two SABCS 2026 abstracts and posters on December 9, 2026, support a more favorable fundamental outlook.
Bears say
Greenwich LifeSciences is facing a weak fundamental setup because it had only $5.9M in cash at the end of September 2026 while operating cash burn was ($3.0M) in 3Q26, leaving limited liquidity to support day-to-day operations. The company also appears dependent on capital markets, since additional funding is needed within the next 12 months and management expects to raise capital through the sale of equity and/or debt securities. That financing need, combined with the ongoing FLAMINGO-01 trial, raises dilution and balance-sheet risk and underscores a stretched funding profile for a clinical-stage biopharmaceutical company.
This aggregate rating is based on analysts' research of Greenwich Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Greenwich Lifesciences (GLSI) Analyst Forecast & Price Prediction
Start investing in Greenwich Lifesciences (GLSI)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Greenwich Lifesciences (GLSI) Forecast
Greenwich Lifesciences (GLSI) Analyst Forecast & Price Prediction
Start investing in Greenwich Lifesciences (GLSI)
Order type
Buy in
Order amount
Est. shares
0 shares